InnoMed PredTox is one of two main FP6 research initiatives jointly funded under the name of InnoMed – Innovative Medicines for Europe

InnoMed is coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a body representing the research-based pharmaceutical industries and biotech SMEs operating in Europe. It is part funded by the European Commission Life Sciences, Genomics and Biotechnology for Health Priority (Ref. LSHB-CT-2005-518170) with a grant of €8M.

While both InnoMed initiatives are aimed at reducing key bottlenecks in the R&D process, AddNeuroMed focused on identifying new biomarkers for Alzheimer’s dementia, whereas InnoMed PredTox is searching for markers to predict the toxicity of drug candidates.

Innomed PredTox Key Facts

  • Toxicogenomics (drug development)
  • Assessing the value of combining results from omics technologies together with the results from more conventional toxicology methods for more informed decision making in preclinical safety evaluation
  • 19 partners (14 pharma companies, 3 universities, 2 technology providers)

InnoMed PredTox Members


Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma will make a contribution to medical progress and strives to improve the quality of life. Bayer Schering Pharma joined the InnoMed Consortium which is fully in line with its mission to make new safe and more effective medicines available to the patients. For more information, please visit:

Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues exceeding $1.2 billion in 2006. For more information, visit:

Boehringer Ingelheim
Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. The focus is on the production of innovative drugs and treatments that represent major therapeutic advances. Worldwide, Boehringer Ingelheim employs more than 3,300 scientists, technicians and support personnel in preclinical R & D. They are complemented by about 2,300 clinical monitors, statisticians and data managers in clinical development and medical departments. Boehringer Ingelheim's R&D staff conducts research in respiratory, oncology, immunology, inflammation, cardiovascular, metabolism, virology and central nervous system diseases.
The Department of Non-Clinical Drug Safety is responsible for the toxicological assessment of new compounds during their development and on the market. The skill set of this department includes the methods of „traditional“ toxicology as well as new “omic” technologies. The department has several years of experience with different platforms such as Affymetrix, and leading database-providers in this field (e.g. Gene Logic Inc.). For more information, please visit:

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. Our partnership with InnoMed PredTox is led by the Genedata Expressionist business unit.
Through close interaction with customers and partners, Genedata has become an opinion leader in toxicogenomics. The Genedata Expressionist® software system enables integrated analysis of high throughput molecular data from transcriptomic, proteomic and metabolomic investigations, and provides a framework for combining this data with conventional toxicology or clinical chemistry information.
Within InnoMed PredTox, Genedata is acting as the central infrastructure professional service provider for data storage, processing and analysis. The company provides expert staff, its products and specially customized software. Genedata leads two consortium Work Packages, namely “Design, construction, maintenance and population of the integrated database” and “Data processing and development of bio-statistical models”.
For more information, please visit:

Johnson & Johnson Pharmaceutical R & D
Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) is one of the fastest-growing global pharmaceutical research & development (R&D) companies and part of the world's most comprehensive and broadly based healthcare company, Johnson & Johnson. With more than 3,500 employees, our R&D reach extends to more than 70 countries worldwide. Our primary facilities include headquarters in Raritan, New Jersey and facilities in La Jolla, California; Beerse, Belgium; High Wycombe, United Kingdom; Schaffhausen, Switzerland; Spring House, Pennsylvania; Titusville, New Jersey; Toledo, Spain; and Val de Reuil, France. Our pledge is to bring to market high-value, cost effective products that treat disease and significantly improve the health and lifestyles of people worldwide. To this end, we are focused on building a robust and innovative product portfolio that comprises a strategic mix of novel targets and fast followers; in-house and in-licensed compounds; and focus on areas of traditional therapeutic strength and new and unmet medical need. For more information, please visit:

Merck KGaA
Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped by 35,091 employees in 62 countries ( Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. The MERCK group has a strong commitment to research and development with one tenth of its work force engaged in this field. To ensure that up-to-date methods are applied Merck is also participating in projects funded by the German government (BMBF) as well as the EC (e.g. Innovative Medicines for Europe)." For more information, please visit:

Merck-Serono / RBM
Istituto di Ricerche Biomediche « A. Marxer » RBM, founded in 1969 is a joint-stock Company owned by Serono in 1982 and since January 2007 by Merck KGaA. From 2000 the site has been fully dedicated to preclinical development spanning from early phases of research to FIM and beyond with an integrated platform. RBM develops safe and effective targeted medicines that improve human life. Preclinical Safety, PK/PD, Quality Control, Quality Assurance, Project Management, DMPK & Scientific Computing, Bioanalytics, Research Pharmacology work together to assure this goal. RBM takes part in InnoMed PredTox doing two 14-days tox studies and the transcriptomics. For more information, please visit:

Novartis is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. Novartis was created in 1996 through the merger of the Swiss companies, Ciba-Geigy and Sandoz. Our name, derived from the latin novae artes, means "new skills" and reflects our commitment to bringing new healthcare products to patients and physicians worldwide. Novartis Pharma develops and markets patent-protected prescription drugs to treat a number of diseases and conditions, including cardiovascular diseases, cancer, central nervous system disorders, organ transplantation, dermatological diseases, respiratory disorders and arthritis. Improving drug safety is one important element in this endeavor. Novartis applies novel technologies and approaches e.g. regulatory toxicology in concert with 'omics' technologies with the aim to identify the best possible compounds for development, to increase the understanding of adverse effects, and to identify relevant biomarkers.These innovations will help improve patient safety by rigorous and early selection of compounds with favorable safety profiles. For more information, please visit:

Novo Nordisk A/S, DK
With a history that spans more than 80 years, Novo Nordisk A/S is a worldwide pharmaceutical company with production facilities in seven countries and affiliates or offices in 68 countries. Novo Nordisk A/S portfolio contains products within four main therapy areas: diabetes care, haemostasis management, growth hormone therapy and hormone replacement therapy. The workforce consists of 23,610 employees (2006) with approximately 50 % of the employees located in Denmark. 4,105 of the workforce is employed within research and development. In 2006, Novo Nordisk A/S had a net turnover of 38,743 million DKK and used 16.3% on research and development.
Novo Nordisk A/S has in recent years successfully implemented state-of-the-art genomics-, proteomics- and metabonomics-platforms in research, as tools to identify biomarkers and elucidate molecular mechanisms of toxicity. This has been done in an effort to provide improved basis for drug candidate selection. During this period, Novo Nordisk has obtained unique skills and experience in interpretation [1] and integration [2] of data generated by these technologies. Novo Nordisk’s experience also include participation in the Consortium for Metabonomic Toxicology (COMET) [3], formed to generate a database consisting of metabonomics data for a wide range of model toxins and multivariate statistical models for prediction of toxicity. For more information, please visit:

Nycomed is a pharmaceutical company of 12,000 people united by a desire to improve the quality of patient's lives. Our mission is to bring medicines that make a real difference to both patients and healthcare providers. To do this, the company provides medicines nad products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region, Nycomed has a presence in about 50 markets worldwide.
We believe that everything we do matters to someone. So we focus on results and respond quickly to the needs of patients and healthcare providers. By doing this, we can achieve our vision of being the preferred pharmaceutical company. For more information, please visit:

Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon ( seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel. For more information, please visit:

Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, we have been active in the discovery, development, manufacture and marketing of novel healthcare solutions. Our products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life.
Our focus is not just the diagnosis and treatment of manifest disease. The integrated healthcare approach is increasingly offering ways of identifying and targeting diseases early, when their damaging effects can still be prevented.
Arranged in two operative divisions, our global mission today and tomorrow is to create exceptional added value in healthcare. These two units are Pharmaceuticals and Diagnostics. For more information, please visit:

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH is the German affiliate within the sanofi-aventis group. With a workforce of 10,000 people - 1,900 of them in R&D - it is the leading player in the German R&D-based pharmaceutical industry. The site in Frankfurt is the biggest R&D site of the sanofi-aventis group. The activities at this site focus on three therapeutic areas: cardiovascular diseases, diabetes / metabolic diseases and thrombosis.
Sanofi-aventis Recherche & Dévelopement
Sanofi-aventis Recherche & Dévelopement group together more than 5,500 people working on 11 R&D sites in France. The main research activities center around the therapeutic areas of neurobiological diseases, oncology, internal medicine, cardiovascular diseases, thrombosis & angiogenesis and exploratory research.
Within the Drug Safety Evaluation department, the Exploratory Safety group aims at investigating mechanisms of toxicity of new drug candidates, applying early and exploratory toxicology to specific projects with particular focus on biomarkers, toxicogenomics, metabonomics, and toxicoproteomics using differential 2D-gels and SELDI technologies. For more information, please visit:

The Servier Group, present in 140 countries with 20 000 employees, including 2 600 in R&D, is the first independent French pharmaceutical Group and the second French pharmaceutical Group worldwide. Its turnover is around of 3.3 billion euros with almost 25 % is dedicated to R&D. 82% of Servier drugs are achieved internationally and 670 million boxes of drugs were produced for patients by the different production sites. The toxicological facilities are located in Gidy (Biologie Servier) with a staff of 110 employees. Within the perfectly well-driven and motivating InnoMed consortium, Servier provided 1 proprietary compound, participated to 3 workpackages (compound selection, study design, metabonomics) and conducted 1 in-life study being also involved in 3 metabonomics studies. For more information, please visit:

UCD Conway Institute
The UCD Conway Institute of Biomolecular and Biomedical Research is a major new research enterprise at University College Dublin. The research programme at UCD Conway Institute focuses on biological molecules, examining how individual molecules contribute to the normal operation of our cells and organs, and how this is disrupted by disease.
Professor William Gallagher, a principal investigator in the UCD Conway Institute, is a member of the InnoMed consortium, specifically the predictive toxicology group that is aimed at discovering biomarkers for early time points of drug toxicity. His team is utilising SELDI technology to search for predictive proteomic markers, as well as digital slide scanning and tissue microarray technology to advance use of histological specimens for high-throughput biomarker validation. For more information, please visit:

University of Hacettepe
Hacettepe University (HU) is a leading university in Turkey with a student population of more than 30,000 and an academic staff of 3279. The Faculty of Pharmacy and the Faculty of Medicine are located in the medical centre along with the HU hospitals and this position facilitates the collaboration in research. HU also provides a high quality medical care to the patients with the experienced clinicians and well-equipped hospitals.
The academic staff from the Faculty of Pharmacy and the Faculty of Medicine will contribute to this project at the last stage with mechanistic and confirmatory follow-up experiments depending on the results obtained. For more information, please visit:

Würzburg Institute of Toxicology
The Institute of Toxicology in Würzburg has a track record of internationally acclaimed research on the mechanisms of toxicity, biotransformation of xenobiotics and studies related to interactions of biologically reactive intermediates with cellular macromolecules and function. The laboratory is/was funded by the European Union, the Deutsche Forschungsgemeinschaft, the Bundesministerium für Forschung und Technologie, the Umweltbundesamt, the US EPA, the US HEI, industry and a number of foundations. The equipment is at the cutting edge of technology and includes excellent animal facilities, specially designed radioisotope laboratories, a full array of cell/molecular biology and analytical chemistry techniques including various equipment for electrophoresis & blotting, microscopy, PCR, GC-MS with different ionisation techniques, LC-MS/MS with electrospray and atmospheric pressure chemical ionisation interfaces, and liquid chromatography coupled to a linear ion trap mass spectrometer. For more information, please visit: